All Oncology News

Rachel C. Jankowitz, MD, discusses the range of risk associated with HR-positive, HER2-negative breast cancer and the importance of communicating with patients about associated adverse events.

Kristen N. Ganjoo, MD, discusses the diagnosis, presentation, and management of patients with uterine leiomyosarcoma.

The FDA has approved romiplostim for the treatment of pediatric patients aged ≥1 year with immune thrombocytopenia for at least 6 months who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy.

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended approval of brentuximab vedotin for use in combination with chemotherapy as a frontline treatment for adult patients with CD30+ stage IV Hodgkin lymphoma.

Ajai Chari, MD, discusses some of the available and anticipated combinations for use in patients with relapsed/refractory multiple myeloma.

CT-P6, a proposed biosimilar to trastuzumab, exhibited long-term disease-free survival and overall survival similar to the reference product in the treatment of patients with HER2-positive early breast cancer.

Benjamin L. Maughan, MD, PharmD, discusses the activity of the combination of radium-223 and enzalutamide in patients with metastatic castration-resistant prostate cancer.

Akihiko Shimomura, MD, PhD, discusses the rationale for the phase III HERB TEA trial of elderly patients with HER2-positive breast cancer.

Amishi Desai, MD, highlights new and emerging data regarding the use of immunotherapy in patients with non–small lung cancer.

Valerie Sugiyama, MD, discusses the treatment of patients with recurrent ovarian cancer.

Paul R. Eber, MD, discusses how the findings from CARMENA impact metastatic renal cell carcinoma treatment and what challenges remain.

Single-agent venetoclax (Venclexta) led to durable responses in patients with relapsed/refractory mantle cell lymphoma with a low rate of late-onset toxicities.

The European Medicines Agency’s Committee for Medicinal Products for Human Use recommended to expand the approval of single-agent rucaparib as a maintenance therapy in adult patients with platinum-sensitive relapsed high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy.

Maurie Markman, MD, discusses the evolution of biosimilars and ongoing efforts to make treatments more affordable for patients with cancer.

Manju P. Paul, MD, discusses new diagnostic and staging techniques that are advancing standards of care in patients with lung cancer.

Almost half of adult patients with previously treated chronic immune thrombocytopenia achieved major responses with the SYK inhibitor fostamatinib (Tavalisse).

C. Ola Landgren, MD, PhD, discusses the role of minimal residual disease negativity and the emergence of CAR T-cell therapy in multiple myeloma.

Thomas Powles MBBS, MRCP, MD, discusses the changes to the frontline landscape of bladder cancer and where research should focus moving forward.

Most pediatric patients with immune thrombocytopenia had rapid and durable platelet responses when treated with the thrombopoietin fusion protein analog romiplostim.

Nonpediatric young adults with stage III/IV Hodgkin lymphoma had significantly better progression-free survival when treated with brentuximab vedotin and conventional chemotherapy compared with standard therapy.

Robert Andtbacka, MD, discusses the current use of talimogene laherparepvec in melanoma and future directions with this type of treatment.

Adding the BTK inhibitor acalabrutinib to bendamustine and rituximab induced high overall response rates in both treatment-naive and relapsed/refractory patients with mantle cell lymphoma.

Nivolumab demonstrated durable response and overall survival rates in a real-world analysis of patients with platinum-refractory, recurrent/metastatic head and neck squamous cell carcinoma.

Stephen L. Graziano, MD, discusses available and emerging targeted therapies for common driver mutations in patients with non–small cell lung cancer and the sequencing strategies beyond frontline treatment.

An investigational antibody directed against Dickkopf-3 may be the key in suppressing tumor growth and extending survival in patients with pancreatic adenocarcinoma.

Adham Jurdi, MD, discusses how the updated data from the PACIFIC trial have changed the standard of care for patients with stage III non–small cell lung cancer.

Scott T. Tagawa, MD, MS, discusses the clinical significance of recent clinical trial data in patients with nonmetastatic prostate cancer.

Patients with newly diagnosed or relapsed/refractory chronic lymphocytic leukemia achieved objective response rates as high as 100% with either of 2 doses of the BTK inhibitor acalabrutinib, results of an open-label phase II trial showed.

The Association of Community Cancer Centers is pleased to announce the hiring of Leigh M. Boehmer, PharmD, BCOP, as Medical Director, Education, for the association’s expanding education initiatives.

Shannon L. Puhalla, MD, discusses some of the advances being made in systemic treatment for patients with brain metastases from breast cancer.